Rigel Pharmaceuticals (RIGL) Scheduled to Post Quarterly Earnings on Thursday

Rigel Pharmaceuticals (NASDAQ:RIGL) is set to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Rigel Pharmaceuticals to post earnings of $0.01 per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Rigel Pharmaceuticals (NASDAQ:RIGL) last announced its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.31. The business had revenue of $36.84 million during the quarter, compared to the consensus estimate of $32.38 million. During the same period in the previous year, the business posted ($0.40) EPS. On average, analysts expect Rigel Pharmaceuticals to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Rigel Pharmaceuticals Price Performance

Shares of NASDAQ RIGL opened at $14.50 on Wednesday. Rigel Pharmaceuticals has a 1-year low of $7.48 and a 1-year high of $17.30. The business’s 50 day moving average is $14.52 and its two-hundred day moving average is $11.68. The stock has a market capitalization of $255.13 million, a P/E ratio of -16.86 and a beta of 0.96.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. StockNews.com upgraded shares of Rigel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, October 18th. Cantor Fitzgerald reissued a “neutral” rating and set a $15.00 target price on shares of Rigel Pharmaceuticals in a research note on Friday, September 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $57.00 price target on shares of Rigel Pharmaceuticals in a research note on Friday, October 25th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.13.

Rigel Pharmaceuticals Company Profile

Rigel Pharmaceuticals, Inc, a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer.